General Electric
Also known as: Canadian Heads of Academic Radiology-GE Healthcare Development Award | GEHC (Sponsor) | GE Healthcare | GE HEALTHCARE | GE Healthcare Bio-Sciences | GE Healthcare Ltd | GE HLTHCARE | GE HLTHCARE INC | GEN ELECTRIC | General Electric | General Electric Healthcare Life Sciences | Pharmaceutical Product Development, LLC
Highest phase reached
Phase 4
First clinical trial
Sep 1, 2003First marketed drug
Jul 16, 1951First NDA
Jul 16, 1951Last known activity
Mar 31, 2026
Timeline
1890s
- Jan 1, 1892
General Electric— Founded
1970s
- Dec 16, 1977
gallium citrate ga 67— NDA Secondary Org
1980s
- Dec 28, 1984
iodohippurate sodium i-123— NDA Organization
- Dec 28, 1984
iodohippurate sodium i-123— Marketing Organization
2000s
- Jan 1, 2004
Amersham— Acquired
2010s
- Feb 25, 2019
Danaher— Acquired By
2020s
- May 6, 2021
Zionexa— Acquired
Drugs by trial phase (79 distinct, 105 trials)
Phase 4 (22 own, 1 via acquisition)
Phase 3 (13 own, 1 via acquisition)
Phase 2 (17 own, 2 via acquisition)
Phase 1 (14 own, 0 via acquisition)
Other trials (9 own, 0 via acquisition)
Indications
Approved for
Studied for
- Alzheimer Disease
- Amyloidosis
- Arterial Occlusive Diseases
- Atrophy
- Body Weight
- Breast Neoplasms
- Carcinoma, Renal Cell
- Cardiomyopathies
- Carotid Artery Diseases
- Chronic Pain
- Cognitive Dysfunction
- Coronary Artery Disease
- Coronary Disease
- Dementia
- Dementia, Vascular
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Embolism
- Fatty Liver
- Fever
- Glioma
- Head and Neck Neoplasms
- Heart Diseases
- Heart Failure
- Hydrocephalus
- Hydrocephalus, Normal Pressure
- Hypertension, Pulmonary
- Hypothyroidism
- Infarction
- Ischemia
- Kidney Diseases
- Kidney Failure, Chronic
- Kidney Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Promyelocytic, Acute
- Lewy Body Disease
- Liver Diseases
- Lung Neoplasms
- Melanoma
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Multiple System Atrophy
- Myocardial Ischemia
- Neuralgia
- Neuroblastoma
- Nociceptive Pain
- Non-alcoholic Fatty Liver Disease
- Parkinson Disease
- Pheochromocytoma
- Prostatic Neoplasms
- Pulmonary Embolism
- Recurrence
- Renal Artery Obstruction
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Sarcoma
- Sclerosis
- Shy-Drager Syndrome
- Supranuclear Palsy, Progressive
- Syndrome
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
- Uterine Neoplasms
- Ventricular Dysfunction
- Ventricular Dysfunction, Left
- Yellow Fever
Marketed drugs (43)
- sodium fluoride (18F)
- succimer
- etidronic acid
- fluoroestradiol
- flurpiridaz
- flutemetamol F-18
- gadodiamide
- gadoteric acid
- gallium citrate ga 67
- calcium
- albumin (Human)
- cyanocobalamin
- ioflupane i-123
- iohexol
- meglumine
- radiolabeled albumin technetium Tc-99m albumin colloid kit
- technetium tc-99m sulfur colloid kit
- technetium tc-99m tetrofosmin kit
- xenon xe-133
- regadenoson
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT07219238Lead sponsorPhase 2/Phase 3Mar 31, 2026
- NCT07169825CollaboratorN/AFeb 13, 2026
- NCT06630845CollaboratorN/ANov 30, 2024
- NCT06398730Lead sponsorPhase 1Jul 2, 2024
- NCT06398730OfficialPhase 1Jul 2, 2024
- NCT06014905CollaboratorPhase 1Sep 1, 2023
- NCT05636852Study directorPhase 2Feb 13, 2023
- NCT05636852Lead sponsorPhase 2Feb 13, 2023
- NCT05634954Lead sponsorPhase 1Jan 31, 2023
- NCT05634954OfficialPhase 1Jan 31, 2023
- NCT05629689Lead sponsorPhase 1Dec 1, 2022
- NCT05629689Study directorPhase 1Dec 1, 2022
- NCT05569278Lead sponsorPhase 1Aug 22, 2022
- NCT05569278Study directorPhase 1Aug 22, 2022
- NCT05486182CollaboratorPhase 4Feb 8, 2022
Details
- Founded
- Schenectady, NY, US Jan 1, 1892
- First NDA
- Jul 16, 1951
- Last known activity
- Mar 31, 2026
Designations held
- Orphan drug
- Priority review